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Summary
A T cell line termed DIL2 has been derived from an infant with a polyclonal T cell receptor
(TCR)/CD3 cell surface expression defect . Indirect immunofluorescence showed that the expression
of certain TCR/CD3 epitopes (like those detected by WT31 and BMA031 monoclonals) was
strongly reduced (around five-fold) on DIL2, whereas other epitopes (like those detected by SP34
and Leu4) were only around two-fold lower than in normalT cell lines. Specific immunoprecipitates
of surface-radioiodinated DIL2 cells containedTCRcx, TCR IQ, CD3-6, CD3-e and TCRr chains,
but lackedCD3-y . This structuralTCR/CD3 variant was, however, capable oftransducing certain
act,ivation signals, since normal proliferation and a low but significant calcium flux was observed
in DIL2 cells after engagement with specific antibodies. Our data suggest that a functional
TCR/CD3 complex can be expressed on the surface of T cells in the absence of CD3-y .
T lymphocytes recognize nominal antigens by means of
a clonally distributed hetero-oligomeric cell surface struc-
ture termed TCR/CD3 complex (1) . The TCR consists of
a disulfide-linked Ig-like heterodimer (TCRas or, in some
cases,TCRy6), noncovalently associated with several invar-
iant proteins with large cytoplasmic regions, namedCD3-y,
CD3-6, CD3-e, TCR-~, andTCR 71 . These structural fea-
tures immediately suggest disparate roles for each group of
chains in TCR/CD3 function : TCR heterodimers are en-
dowed with antigen-recognition properties, whereas the non-
polymorphic components are probably in charge ofinducing
the multiple intracellular events that take place duringT cell
activation (among them, hydrolysis of phosphatidylinositol,
calcium mobilization and the transcription of the gene for
IIr2) . Indeed, perturbation of the CD3 structure with anti-
bodies appears to mimic, on a polyclonal fashion, the physio-
logical engagement of the TCR by antigen (2) . Activated
T lymphocytesmay thereafter acquire a range of effector func-
tions which can be measured in vitro as proliferation or
cytokine secretion. How the invariant party of the TCR
generates such a wide array ofbiochemical events is still poorly
understood, although its structural complexity allows for cer-
tain degree of functional specialization. Based on extracel-
lular/intracellular homologies, it has been suggested, for in-
stance, that CD3-y and CD3-6 are closely related subunits
with very similar functions, whereas CD3-e ismore distantly
related and may therefore have a distinct role in CD3 func-
tion (1) . More recently, the ~ chain has been elegantly shown
to be sufficient to initiate receptor-induced T cell activation
(3) . Also, ~-rl heterodimers have been involved in coupling
TCR occupancy to phosphoinositide hydrolysis in the mouse
(4) . Several groups have approached the analysis of struc-
ture/function relationships within theTCR/CD3 by studying
T cell mutants, transfectants, lymphomas, or hybridomas with
peculiarTCR/CD3 compositions (4-9) . Their main conclu-
sion is that normal surface expression and function of
TCR/CD3 requires the presence ofall its components . How-
ever, not all possible mutants have been analyzed. In partic-
ular, T cells lacking only CD3-y, CD3-6, or CD3-e have
not been described to date.
In the present paper, the characterization ofa naturalhuman
mutant T cell line (DIL2), derived from an individual with
a TCR/CD3 expression defect (10, 11) is reported. The sur-
face TCR/CD3 complex of this T cell line was shown to
containTCRcx,TCRa, CD3-6, CD3-e, and TCR 'chains,
but not CD3-y. Functional analyses indicated, in two ofthree
assays (proliferation and calcium flux, but not IIr2 synthesis),
that this TCR/CD3 variant retained certain signal transduc-
tion ability. We conclude that a CD3-y- TCR/CD3 com-
plex can be expressed and triggered on the surface ofhuman
T cells.
Materials and Methods
Cell Lines.
￿
Cell lines were derived from PBLs cultured inRPMI
1640 medium containing10% FCS (Flow Laboratories, Rockville,
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3 d, cells were reestimulated weekly with 50 IU/ml of rIIr2 (kindly
provided by Hoffmann-La Roche, Nutley, NJ), and, in some cases,
also with an inactivated mixture (ratio 1/4) ofallogeneic lympho-
cytes andEBVtransformed lymphoblastoid cells (GUS-1) . T cells
from a mild case ofTCR/CD3 immunodeficiency (D, reference
11) as well as from differentnormal individuals (generically named
C) were cultured in parallel during 1-2 mo, and the latter were
used as controls in all experiments .
Antibodies .
￿
Several mAb were used for cytofluorometric anal-
yses. Their names, specificities, Ig isotypes and sources are listed
in Table 1 . For specific immunoprecipitations, the following re-
agents were used : mAb SP34 is a murine IgG3 which recognizes
CD3-e (12), mAb APA1/2 recognizes CD3-S (Fig. 2D) andboth
were obtained byimmunization ofBalb/c mice with purifiedhuman
CD3 proteins ; mAbHMT3.2 recognizes CD3-,y (Fig . 2 D), was
obtained by immunization of armenian hamsters with purified
human CD3 proteins and was generously donated by Dr. Ralph
Kubo (National Jewish Center, Denver, CO); mAb OKT3 was
a generous gift from Dr. G. Goldstein (Ortho Pharmaceuticals,
Raritan, NJ); TG5 is a rabbit antiserum raised against the CD3--y
C-terminal peptide GLQGNQLRRN andwaskindly donatedby
Dr. Denis Alexander (Cambridge Research Station, UK); J31 is
a rabbit antiserum raised against the last 13 C-terminal aminoacids
of human CD3-S (Alarcon, B., S . C. Ley, F. Sanchez-Madrid,
R. S . Blumberg, S.TJu,M. Fresno, andC. Terhorst, unpublished
results) ; N40 is a rabbit antiserum raised against ahuman TCR-('
peptide (Sancho, J., andC. Terhorst, unpublished results); C41 is
a rabbit antiserum that reacts with the constant region of HLA
class I heavy chains (13) .
Cytofluorometry .
￿
Cells (105-5 x 105) were incubated at 4°C for
30 minwith appropriate amounts ofeither fluorescein-conjugated
or purified mAbs (Table 1) in 100 pl of PBS containing 1% FCS .
After two washings, F(ab')2 goat anti-mouse IgG (Ortho Phar-
maceuticals, Raritan, NJ) was used as asecond step reagent before
cytofluorographic analysis of 10^ cells in an Epics C cell sorter
(Coulter Electronics, Hialeah, FL) . Quantitative comparisons of
fluorescence intensities was performed with an appropriate pro-
gram which calculated themean fluorescence in linear scale for each
sample (Epics cytologic software 2.01 ; Coulter) .
Antibody-Binding Radioimmunoassays.
￿
The reactivity of different
mAbs withT cell lineswas tested byRIA as described (14) . Briefly,
5 x 10^ cells were labeled with an excess of mAb, washed three
times and developed with 100,000 cpm of "'I-labeled rabbit
anti-mouse F(ab')2 antibody for 1 h at 4°C . After washing three
times, cells were transferred into tubes for y counting.
Radiolabeling and Immunoprecipitation . For the iodination of
membrane proteins on the cell surface, 10' cells were washed with
PBS, centrifuged and resuspended in 200 IA1 ofPBS. 2 mCi ofNa
1251 (Amersham, Buckinghamshire, UK) and 25 pl of a lactoperox-
idase/glucose-oxidase mixed solution (50 IU/ml and 10 IU/ml,
respectively; SigmaChemical Co ., St . Louis,MO) were added (15) .
Finally, 50 ul aliquots of a 200 mM glucose solution were added
two times at 10-min intervals . The reaction was stopped by diluting
the mixture in 10 ml of 20 mM potassium iodide in tyrosine-
saturated cold PBS . For metabolic labeling, 10' cells were washed
with PBS and resuspended in 1 ml ofMEM without methionine
or cysteine and incubated in a 5% C02 incubator for 3 h in the
presence of 0.5 mCi of a"S-methionine and s5S-cysteine mixture
(Amersham) . After labeling, cells were collected by centrifugation
at 1.500g for 5 min and lysed in a buffered solution of1% NP40
containing several proteinase inhibitors (16) .
Immunoprecipitation stepswere carried out at 4°C. Briefly, the
lysates were cleared twice by ultracentrifugation. and precleared
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three times by incubation with protein-A sepharose beads (Phar-
macia Fine Chemicals, Piscataway, NJ), previously coated with non-
immune serum . Finally, the supernatant from the last preclearing
was incubated for 4 h with 2.5 Al of protein-A sepharose beads
previously coated with the specific monoclonal or polyclonal anti-
body (see above) . Electrophoresis was performed on 12.5% poly-
acrylamide gels in the presence of sodium dodecyl sulfate . Gels were
dried and exposed to Kodak XAR-5 X-ray film . Gels with "S-
labeled protein samples were fixed in a7.5% acetic acid, 20% eth-
anol solution and soaked for 1 h in 1M sodium salicylate (Sigma
Chemical Co.) before drying. In some cases, immunoprecipitates
were deglycosylated before electrophoresis. To this end, samples
were concentrated by addition of 1 ml acetone and incubated 1 h
at -70°C. Samples were centrifuged at 12,000g for5min at 4°C,
the supernatant removed and the pellet was left to air dry. The
dried immunoprecipitates were boiled for 3min in 14 P,1 of a0.5%
SDS,0.8% 2-ME solution . The sampleswere then allowed to cool
and mixed with 28 ttl of 0.25M phosphate buffer (pH 8.6) con-
taining 10mM phenanthroline (Sigma ChemicalCo.) . Half ofeach
sample was incubated overnight at 30°C in the presence of0.25
IU ofN-glycosidase F (Genzyme, Boston, MA)andthe other half
was left untreated .
Southern and Northern Blotting Analysis.
￿
TotalDNA or RNA
was prepared from cell lines, digested with endonucleases in the
case of DNA, subjected to electrophoresis, blotted, hybridized,
washed and autoradiographed as described previously (17) . The fol-
lowingDNA probes were obtained and labeled as described (18) :
TCR-tx, TCR-a, CD3-,y, CD3-S, CD3-e, TCR-(' and 0-actin .
Functional Assays.
￿
Proliferation assays were set up in 96-well
round-bottomed microtiter plates (8 x 10^ cells per well in 0.2
ml; Costar, Cambridge, MA) . Increasing dilutions ofmAbin Tris
50 mM, pH 8, were incubated in plates overnight at 4°C. The
plates were then washed three times with 199medium (Flow Labora-
tories) to eliminateunboundmAb. Cells in RPMI with 10% FCS
were incubated in the plates for 3 d in a controlled humidity chamber
at 5% C02 and 37°C. In some cases, inhibition ofT cell prolifer-
ationwas assayedby adding increasing amounts ofanti-CD3 (Leu4,
5-70 ng/ml), anti-CD25 (0.3-10 P,g/ml ; Coulter Electronics, Hia-
leah, FL)or anti-IL-2 mAb (3-50 14g/ml ; Genzyme), at the begin-
ning of the cultures. Proliferation was measured by 3H-thymidine
uptake after 72 h as previously described (18) .
For 11,2 production assays, 16 x 10' cells were incubated in the
presence of plastic-bound mAb or inactivated allogenic cells in a
medium containing anti-CD25 (10pg/ml) to avoid autologous use
of secreted IL2. Maximum synthesis of 11,2 was induced with 1
,uM Ionomycin (Sigma Chemical Co.) plus 12 ng/ml phorbol
myristate acetate (Sigma Chemical Co .) plus a 1/60,000 dilution
ofan anti-CD28mAb (Kolt2, generously donated by Dr. K. Sagawa,
Kurume University,Japan) . Supernatants oftriplicate experiments
were collected at day 3 for an IL-2 bioassay using CTLL2 (19) .
Calcium mobilization during stimulation with 10,ug/ml of anti-
CD3 mAb (SP34) and crosslinking with 30,ul of anti-mouse Ig
antiserum(Cappel Laboratories, Malvern, PA) was analyzed using
cells pre-loaded with the calcium-sensitive fluorescent dye Indo-1
(3,uM; Molecular Probes, Junction City, OR) . Maximumcalcium
influx was induced with 1 P.M Ionomycin. Quantitative compar-
isons of cytofluorometric results were performed as stated above
(under Cytofluorometry) .
Results
Expression oftheT Cell Recepfor Complex.
￿
Analysis by cyto-
fluorometry of severalT cell lines derived from a mild case
ofTCR/CD3 immunodeficiency (showing low levels of sur-
Lacking CD3--yThe reactivity of each mAb against DIL2 was analyzed by immunofluorescence and flow cytometry as described in Materials and Methods. The
mean linear fluorescence fraction reflects the quantitative binding of each mAb to DIL2, relative to a normal T cell line . The symbols (+ + + + ),
(+ + +), (+ +), (+), and (-) denote reactivity patterns with DIL2 comparable to OKT11, Leu4, OKT3, WT31, and MsIgG, respectively (Fig .
1) . ' ND not determined .
face TCR/CD3 in peripheral bloodT lymphocytes) (11) re-
vealed that their expression of certain TCR/CD3 epitopes
became progressively higher upon culturing in IIr2containing
media. This may reflect the selection imposed by our partic-
ular culture conditions . By 1 to 2mo of culture, the expres-
sion of several T cell markers in one of these CD4 positive
T cell lines (DIL2) was as summarized in Table 1, and re-
mained stable thereafter. Quantitative analysis of the cyto-
fluorometric data (shown as mean linear fluorescence frac-
tion in Table 1) indicated that DIL2 had two- to five-fold
less expression ofthe tested TCR/CD3epitopes as compared
to controls. Antibody-binding radioimmunoassaysusingthe
samemAb (Table 1) essentially confirmed these findings (DIL2
expressed around 50% less TCR/CD3 complexes than con-
trols, data not shown) . Also, striking differences were ob-
served in the reactivity patterns of different TCR/CD3-specific
mAb with DIL2 . Thus, most DIL2 cells were positive
(>75%) when stained with CD3-e-specific mAb (Leu4,
SP34, Table 1, Fig. 1) . In contrast, other epitopes like those
recognized by OKT3 andWT31 were detectable in only a
fraction of the cells (<70% and <55%, respectively, Fig. 1) .
Based on these two criteria (fluorescence intensity and reac-
tivity pattern), thefollowingmAbhierarchyfrom higher to
321
￿
Perez-Aciego et al.
U
0
E
relative fluorescence intensity
Figure 1 .
￿
Representative reactivity patterns of antiTCR/CD3 mAbs
with DIL2 (solid line) as compared with a controlT cell line (dots) . Leu4
(anti-CD3-e), OKT3 (anti-CD3-ey+eb) and WT31 (antiTCR-a+M
profiles are shown as logarithm of relative fluorescence vs cell number.
The reactivity profile with OKT11 (anti-CD2) is shown for comparison.
The vertical line in each panel indicates the upper limit of the negative
control staining (MsIgG) .
Table 1. Phenotypic Characterization of DIL2 Cells
Mean linear Reactivity pattern
Name Specificity Isotype fluorescence fraction with DIL2 Source
OKT11 CD2 IgG2a 0.90 + + + + Ortho, NJ
OKT4 CD4 IgG2b 1.20 + + + + Ortho, NJ
DR HLA class II IgG2a 1.30 + + + + B. Dickinson, CA
RIL-2 CD25 IgG2a 1.00 + + + + Coulter, FL
Leu4 CD3-e IgG1 0.55 + + + B. Dickinson, CA
SP34 CD3-e IgG3 0.60 + + + C. Terhorst, MA
T3b CD3-e? IgG2a 0.40 + + J . E . de Vries, HOLLAND
OKT3 CD3-e-y + e8 IgG2a 0.30 + + Ortho, NJ
RW28C8 CD3-e? IgG2a 0.30 + + E. L . Reinherz, MA
RW24B6 CD3-e? IgG2a 0.30 + + E. L. Reinherz, MA
CRIS7 CD3-e? IgG2a 0.25 + + R. Vilella, SPAIN
WT31 TCR-a+ IgG1 0.27 + Sanbio, HOLLAND
BMA031 TCR-a+ IgG2b 0.19 + R. Kurrle, FRG
KOLT2 CD28 IgG1 1.17 + K. Sagawa, JAPAN
Ti-yA TCR-VT9 IgG2a ND" - T. Hercend, FRANCE
TCR61 TCR-C61 IgGl ND - T Cell Sciences, MA
OKT8 CD8 IgG2a ND - Ortho, NJ
MsIgG Neg. control IgG ND - Coulter, FL
X63 Neg. control - ND - F. Sanchez-Madrid, SPAINO
U
1
a
5
Lk- Lk-
7
30
20
DI L2
￿
CONTROL
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Figure 3 .
￿
Calcium mobilization by DIL2 (left panels) as compared to
a controlT cell line (rightpanels) . Both samples were incubated with anti-
CD3, 3 min later with anti-mouse Ig, and finally with Ionomycin (ion),
and analyzed for calcium content changes in an EPICS cytometer (Coulter
Electronics, Hialeah, FL) . Thebasal calcium levels are shown in the upper
panels. The numbers in each panel indicate thepercentage of positive cells
above an arbitrary upper limit defined on the basal profiles by a vertical
line . All panels represent the highest percentage for each treatment .
lower binding ofDIL2 may be deduced: Leu4/SP34 >OKT3/
T3b/RW28C8/RW24B6/CRIS7 >WT31/BMA031(Table
1) . Taken together, these results suggested that most DIL2
cells expressed a relatively high level of the TCR/CD3 com-
plex in their surface.
Absence ofCD3-y.
￿
DIL2 cells were next labeled with 1151
to allow a preliminary biochemical characterization of the
abnormal TCR/CD3 on their cell surface. The results using
an anti-CD3-e (e hereafter) mAb demonstrated the presence
ofmature ao heterodimers associated to e onDIL2 cells (Fig .
2 A, left panel) . However, N-glycanase digestion of anti-e
precipitates, which allowed a clear distinction between y
and
￿
chains, revealed thaty was undetectable inDIL2 precipi-
tates (Fig . 2 A, middle pane . To confirm these results and
to rule out the presence of free y chains on the surface of
DIL2, a direct precipitation was performed with an anti--y
mAb (HMT3.2, characterized in Fig. 2 D) . No y chains could
LEU 4 (p/ml)
￿
OKT 3 (~tg/ml)
Figure4.
￿
Impaired Ih2 synthesis by DIL2 cells (filled symbols), as com-
pared to a control (open symbols) T cell line, after stimulation with in-
creasing amounts of plastic-bound anti-e (Leu4) or anti-e-y+ e6 (OKT3)
mAb. Production ofIL2 was always <0 .5 IU/ml when using only medium
orirrelevant mAbs (OKMI, IgG2b ; OKM5, IgGl ; I-eu5b, IgG2a) . Addi-
tion oflonomycin plus phorbol myristate acetate plus an anti-CD28 mAb
restored normal synthesis levels o£11,2 byDIL2 cells (>100 IU/ml; normal
control >100 IU/ml) .
be detected in these conditions either (Fig. 2A, right panel) .
In contrast, control precipitates revealed normal levels ofHLA
class I proteins in DIL2 lp ysates (Fig. 2A, right panel) . Anal-
ysis by two-dimensional electrophoresis ofthe radioiodinated
material showed that r chains were associated to the surface
TCR/CD3 of DIL2 . It also confirmed that the surface a
and 0 chains ofDIL2 carried mature-type oligosaccharides
(not shown) .
Although no y could be detected on the surface ofDIL2,
it was still possible that some was present in the cytoplasm
but could not associate to the rest of the TCR/CD3 com-
plex for exportation. To rule out this possibility, DIL2 cells
were metabolically labeled and precipitated with antibodies
specific for the different CD3 polypeptide chains (Fig. 2 B) .
The results demonstrated a complete lack ofy product also
in the cytoplasm of DIL2, whereas S and e were readily de-
tectable. Similar results were obtained using an anti-y chain
antiserum (TG5, Fig. 2 C) . Thus, both a monoclonal
(HMT3.2) and an antiserum (TG5) which were specific for
y showed that this chain was not present in DIL2 cells. In
conclusion, the biochemical defect inDIL2 involved primarily
a profound .y protein deficiency. Surprisingly, detectable levels
o mature TCR/CD3 complexes containing a, a, 6, e, and
~, but not y chains, reached the cell surface. It was therefore
of interest to analyze the genes and transcripts coding for
those TCR/CD3 components in DIL2 .
The existence oflarge deletions in they and~chain genes
ofDIL2 was ruled out by Southern blot analysis of genomic
DNA with several restriction enzymes, since no differences
were found between normal and DIL2 cells in the number
and size ofrestriction fragments corresponding to those and
Figure2 .
￿
TheTCR/CD3 complex ofDIL2 cells lacked CD3-y protein. (A) Radioiodination ofDIL2, D, and a control, C, T cell line. Immunoprecipitates
obtained using anti-e (left and middlepanels), anti-7 (HMT3.2, right panel), or anti-HLA class I specific antibodies (right panel) were analyzed by elec-
trophoresis . The middle panel shows the deglycosylation products (N-glycosidase F or N-gly +) of the anti-e precipitate (N-gly -), which allow
the distinction of y and 6 proteins (indicated as dy and d6) . (B) Metabolic labeling of DIL2, D, and a control, C, T cell line. Immunoprecipitates
obtained using non-immune serum (N), anti-e (SP34), anti--y (HMT3.2) or anti-6 031) specific antibodies were analyzed by electrophoresis. (C) Meta-
bolic labeling (with 1 mCi of 35S-methionine, 8 h) of DIL2, D, and a control, C, T cell line. Immunoprecipitates obtained using non-immune serum
(N), anti-e, anti-y (TG5) or anti-1' specific antibodies were analyzed by electrophoresis in non reducing conditions . y could not be resolved from 6
and e in this particular gel. (D) Characterization ofHMT3.2 and APA1/h:COS cells were transfected with 2 g of plasmids pSR-y, MNC8-6 or pSR-e
and labeled, lysed and immunoprecipitated with the indicated antibodies as described in Materials and Methods . NMS is non-immune mouse serum.E
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Figure 5 .
￿
Normal proliferation of DIL2 (filled symbols) and controls (open symbols) to increasing amounts ofplastic-bound anti-e (Leu4) or anti-E-y+ e8
(OKT3), or exogenous rIIr2 . Addition of only medium or an irrelevant mAb (see Fig. 5) always resulted in <5,000 cpm .
all other TCR/CD3 components (not shown) . Interestingly,
an E-specific probe revealed that DIL2 was homozygous for
a previously described 8.1 kb TagI restriction fragment length
polymorphism (20) . This rare genotype (<10% frequency
in normal Spaniards) was shared within the family only by
the other affected sib (V, reference 21) but it is unlikely that
it was directly related to the TCR expression defect, because
it was also found in normal individuals.
To assess the expression of mRNA transcripts encoding
the differentTCR/CD3 components, totalRNA isolated from
DIL2 and a normal control T cell line was analyzed by
Northern hybridization techniques. The results revealed that
some crosshybridizing transcripts for all TCR/CD3 com-
plex chains were present inDIL2 (data not shown) . This ruled
out a complete transcriptional defect for the observed lack
of y in DIL2 .
Functional Analysis.
￿
To determine whether the y- TCR/
CD3 complex expressed by DIL2 was functional with re-
gard to antigen recognition and signal transduction, three
sequentialT cell activation parameters (calcium mobilization,
IL-2 synthesis, and cell proliferation) were independently tested
after TCR/CD3 crosslinking using several anti-CD3 or
antiTCRcig reagents (and, in some cases, appropriate inac-
tivated allogeneic feeder cells) .
First, calcium flux was low but detectable in DIL2 (Fig.
3) . The impairment of calcium mobilization in DIL2 was
a TCR/CD3-specific phenomenon, because addition of a cal-
cium ionophore (which by-passes membrane signals) com-
pletely reverted the defect (Fig. 3, ion) . In contrast, CD3
crosslinking in saturating conditions (10 pg/ml) using an
anti-mouse Ig reagent showed that only a few DIL2 cells
(around 30% compared to more than 70% in controls)
significantly increased their calcium content above basal levels.
In addition, the average increase of calcium concentration in
DIL2 cells was around three-fold lower than in controls (see
Materials and Methods) . Therefore, calcium influx after CD3
crosslinking was impaired, but not absent, in DIL2 .
Second, IL-2 production by DIL2 cells after stimulation
with a wide range of plastic-bound anti-CD3 antibody con-
centrations was found to be markedly impaired as compared
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to a normal T cell line (four- to five-fold lower, Fig. 4) . In-
terestingly, the observed impairment of IL2 synthesisbyDIL2
occurred irrespective of the binding ability of the stimula-
tory mAb (both low, like OKT3 and high, like Leu4) . In
addition, the synthesis of IL2 in response to allogeneic an-
tigens was analyzed in T cell lines derived from the donor
of DIL2 or from normal individuals, cultured in the pres-
ence of an allogeneic lymphoblastoid B cell line (GUS-1) as
described in Materials and Methods. The T cell lines thus
obtained were challenged with either GUS-1 or an irrelevant
(complete HLA mismatch) B cell line, and assayed for IL2
synthesis. Irrelevant B cells consistently induced less than 0.5
IU/ml of IL2 in both control and y
_ cells, and GUS-1 in-
duced around 50 IU/ml ofIIr2 in controls, but less than 5 IU/
ml in y- cells . The impairment in IL-2 synthesis by DIL2
was also shown tobe a TCR/CD3-specific feature, as it could
be reverted by using transmembrane signals (calcium iono-
phore plus phorbol ester) together with mAb against other
surface molecules (CD28, see footnote to Fig. 4) . In conclu-
sion, 11,2 synthesis byDIL2 cells afterCD3 crosslinking (and
by other y- T cells after allogeneic stimulation) was
markedly impaired in vitro .
Third, the proliferation ofDIL2 cells induced by an iden-
tical concentration range ofplastic-bound anti-CD3 mAb was,
in contrast, found to be dose-dependent and comparable to
control T cell lines (Fig. 5) . Similar results were obtained
with all tested anti-CD3 (Leu4, OKT3, T3b, SP34) and
antiTCRcio (WT31) mAb, irrespective of their binding
ability to DIL2 cells (not shown) . The observed prolifera-
tion ofDIL2 to plastic-bound Leu4 could be completely abol-
ished by addition to the cultures of increasing amounts of
soluble Leu4 (data not shown), demonstrating the specificity
of the response. Also, the normal proliferation ofDIL2 cells
in response to both Leu4 and OKT3 wasshown to be depen-
dent on IIr2/IL2 receptor interactions, because addition to
the cultures ofincreasing amounts of anti-IL2 or anti-CD25
mAb effectively abolished their proliferative response in a dose-
dependent fashion (data not shown) .
To rule out that the normal proliferation ofDIL2 to anti-
CD3 challenges was due to an unusually high responsivenessof this T cell line to the low levels of IL2 detected in the
assays (<5 IU/ml, Fig. 4), its proliferative response to exog-
enous rIL2 was titrated out (Fig. 5) . It was found to be similar
to that of normal controls.
Taken together, our results suggest that this particular T
cell line expressing a variant form of surface TCR/CD3 com-
plex which lacked y was nevertheless in part functional, since
it was capable offluxing some calcium and undergoing normal
TCR/CD3-mediated proliferation responses. Also, prolifer-
ation took place through the IIr2/IIT2 receptor pathway, de-
spite the fact that 11,,2 synthesis was markedly impaired in
similar experimental conditions. The observed low levels of
secreted 11,2 byDIL2 must therefore have been sufficient for
its autocrine requirements.
Discussion
A Natural CD3-y Expression Defect.
￿
The surface expres-
sion of partial TCR/CD3 complexes lacking y chains was
shown to be possible inDIL2 . The lack ofy, however, strongly
reduced the expression ofcertain TCR/CD3 epitopes (namely
those recognized by Tab, OKT3, RW28C8, RW24B6,
CR157, WT31, and BMA031), suggesting that this group
ofmAbs require y expression to bind the complex efficiently.
These data correlate with those obtained by others in murine
T cell variants (22), and suggest that afbe~ complexes are
biochemically stable (albeit epitopically altered), andmay reach
the cell surface in certain circumstances (Fig. 1) . Previous
reports have shown that they chain is theCD3 component
that interacts with the cxg heterodimer (23) . However, our
data support that a CD3 chain other than y may also as-
sociate to CO. Because y and S chains are highly homolo-
gous, Swould be the most likely candidate. Therefore, y and
S subunits may be interchangeable and/or expressed on dis-
tinct functional TCR complexes. The recent demonstration
of the existence of two closely associated e chains within the
same surfaceTCR/CD3 complex (9) would suggest the fol-
lowing non-excluding models : cafyeebr2, aayeey~2,
aobeeb~2 . Our data support these hypothetical models .
The virtual absence ofy chains inDIL2 cells by immuno-
precipitation is difficult to explain at present, because some
,y-specificmRNA is detectable by Northern analysis. It could
be proposed that the biochemical basis of the defective pheno-
type may involve a small natural mutation in the gene for
CD3-y . This defect would prevent its normal association to
the rest of the TCR/CD3 complex and also its recognition
by 7-specific mAb, but not the exportation of a partial
TCR/CD3 lacking y chains to the cell surface . However,
since allelic exclusion of the TCR does not operate on CD3
genes, this hypothesis would require the segregation oftwo
independent small mutations (in coding and/or regulatory
regions) into this particular donor (his parents were unrelated,
reference 10) . Interestingly, an e gene polymorphism detected
in the family suggests that the two affected siblings may share
their ybE haplotypes (see above) . We are presently sequencing
DIL2 y cDNA and regulatory genomicDNA segments to
address this issue (see note added in proof) .
Function of a CD3-y- T Cell Receptor (MR)IM Com-
plex. Previous studies withT cell mutants have demonstrated
that the normal expression and function of the TCR/CD3
complex requires the presence of all its components (4-9) .
However, some of these variants did retain certain functional
features, allowing to establish structure/function relationships
(4, 5, 24) . Similarly, DIL2 allows to propose that CD3-y
is dispensable for TCR-induced autocrine proliferation . With
regard to other functional features, it cannot be ruled out
that the impaired calcium flux and IL-2 secretion observed
in stimulated DIL2 cells may have been due to their two-
to five-fold lower antibody-binding ability as compared to
controls. Also, clonal variation and/or the intrinsic hetero-
geneity of a T cell line like DIL2 cannot be ruled out as a
cause of its observed impaired activation features .
Pathological Implications.
￿
It is surprising that the donor
ofDIL2 may himself be viable, unless alternative or redun-
dant pathways ofT cell activation are operative (18) . Indeed,
redundant and overlapping functions among proteins of the
immune system allow the existence ofhealthy immunodeficient
individuals, the most common being congenital C2-, IgA-,
HLA class I- and adenosine deaminase-deficiencies (reviewed
in reference 25) . Recently, a healthy infant with a similar
TCR/CD3 defect has been reported (26) . The biochemical
basis of this deficiency was, however, different from that of
DIL2, andmay involve a S defect (27) . It is therefore tempting
to speculate that b-containing TCR/CD3 and y-containing
TCR/CD3 are in fact redundant recognition structures. The
close evolutionary relationship of S and y genes would sup-
port this concept (28) .
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￿
Perez-Aciego et al .Note added in proof . After submission of this manuscript, a deletereous point mutation was detected in
the initiation codon of DIL2 CD3-y cDNA, which might explain the hindered synthesis of y protein
observed in DIL2 cells.
1986 . A T3-like protein complex associated with the antigen
326 Function of a T Cell Receptor Lacking
receptor on murine T cells . Nature (Lon4 320:272 .
Alarcon, B., B . Berkhout,J. Breitmeyer, andC. Terhorst.1988.
Assembly of the humanT cell receptor-CD3 complex takes
place in theendoplasmic reticulumand involves intermediary
complexes between the CD3-gamma.delta.episilon core and
single T cell receptor alpha or beta chains . J. Biol. Chem.
263:2953 .
Berkhout, B., B . Alarcon, andC. Terhorst . 1988 . Transfection
of genes encoding the Tcell receptor-associatedCD3complex
intoCOS cells results in the assembly of the macromolecular
structure.J . Biol. Chem . 263:8528 .
Regueiro, J.R., M. Lopez-Botet,M.O. De Landazuri, J . Al-
cami,A. Corell,J.M . Martin-Villa,J.L . Vcario, andA. Arnaiz-
Villena. 1987 . An in vivo functional immune system lacking
polyclonal Tcell surface expression ofthe CD3/TCR(WT31)
complex. Scand. J . Immunol. 26:699 .
Gillis, S., M.N . Ferm, andK.A . Smith . 1978 . Tcell growth
factor: parameters of production and quantitative increasing
for activity.J. Immunol . 120:2027 .
Charmley, P., O . Sanal, S . Wei, A. Chou, C. Terhorst, and
R.A . Gatti . 1989 . Human Tcell receptor CD3-e (CD3E)/TagI
DNA polymorphism . Nucleic Acids Res. 17:2374 .
ArnaizVillena,A ., P . Perez-Aciego, C. Ballestin,T Sotelo,C.
Perez-Seoane, J.M . MartinVilla, andJ.R. Regueiro . 1991 . Bio-
chemical basis of a novel T lymphocyte receptor im-
munodeficiency by immunohistochemistry. LAS Invest 64:675 .
Bonifacino, J.S ., C. Chen, J . Lippincott-Schwartz, J.B. Ash-
well, and R.D . Klausner. 1988 . Subuni t interactions within
the Tcell antigen receptor : clues from the study partial com-
plexes. Proc Natl. Acad. Sci . USA . 85:6929.
Brenner, M.B., I.S. Trowbridge, andJ.L . Strominger. 1985 .
Cross-linking of humanT cell receptor proteins : association
between the Tcell idiotype beta subunit and the T3 glyco-
protein heavy subunit . Cell. 40:183 .
Transy,C ., P.E. Moingeon, C. Stebbins, and E.L . Reinherz .
1989 . Deletionof the cytoplasmic region oftheCDR subunit
does not prevent assembly of a functional Tcell receptor. Proc.
Nad. Acad. Sci. USA . 86:7108 .
Alarcon, B., C. Terhorst, A. ArnaizVillena, P . Perez-Aciego,
and J.R. Regueiro. 1990. Congenital Tcell receptor im-
munodeficiencies in man. Immunodef . Rev . 2:1 .
Thoenes, G., F. Le Deist, A. Fischer, C. Griscelli, and B.
Lisowska-Grospierre. 1989 . Immunodeficiency associated with
defective expression of the Tcell receptor-CD3 complex . N .
Engl.J . Med . 322:1399 .
Thoenes, G ., C. Soudais, F . Le Deist, C. Griscelli,A. Fischer,
andB. Lisowska-Grospierre. 1991 . Abnormal biosynthesis, pro-
cessing andmembrane expression of the TCR/CD3 complex
in an immunodeficient child. In Progress in immune deficiency
III .H.M . Chapel, RJ . Levinsky, andA.D.B. Webster, editors .
Royal Society of Medicine Services, London . 307 pp.
Krissansen, G.W ,M.J . Owen,W Verbi, andM .J . Crumpton .
1986 . Primar y structure of the T3y subunit of the T3/T cell
antigen receptor complex deducedfromcDNA sequences: evo-
lution of the T3y and6 subunits. EMBO(Eur . Mot . Biol. Organ)
J . 5:1799 .
CD3-y
References
1 . Clevers, H ., B. Alarcon,T Wileman, andC. Terhorst . 1988 .
The T-cellreceptor/CD3 complex : adynamic protein ensemble. 16 .
Annu. Rev . Immunol . 6:629 .
2. Imboden,J.B., and J.D. Stobo . 1985 . Transmembrane signaling
by theT cell antigen receptor. Perturbation oftheT3-antigen
receptor complex generates inositol phosphates and releases cal-
cium ions from intracellular stores .J. Exp Med . 161:446 .
3. Irving, B.A ., andA. Weiss. 1991 . Thecytoplasmic domain of 17 .
theT cell receptor r chain is sufficient to couple to receptor-
associated signal transduction pathways. Cell. 64:891 .
4. Mercep,M ., J.S . Bonifacino,P . Garcia-Morales, L.E. Samelson,
R.D . Klausner, andJ.D. Ashwell . 1988 . Tcel l CD3-zeta eta 18 .
heterodimer expression andcoupling to phosphoinositide hy-
drolysis. Science (Wash. DC). 242:571 .
5 . Sussman, J.J ., J.S . Bonifacino, J . Lippincott-Schwartz, A.M.
Weissman,T Saito,R.D. Klausner, andJ.D. Ashwell. 1988 .
Failure to synthesize the TcellCD3-zeta chain : structureand 19 .
function of a partial Tcell receptor complex . Cell. 52:85 .
6 . Ley, S.C ., K.N . Tan,R.Kubo,M.S. Sy, andC. Terhorst . 1989 .
Surface expression ofCD3 in the absence of Tcell receptor 20 .
(TCR) : evidence for sorting of partial TCR/CD3 complexes
in a post-endoplasmic reticulum compartment.Eur .J . Immunol .
19:2309. 21 .
7 . Sancho, J., T Chatila, R.C . Wong, C. Hall, R. Blumberg,
B. Alarcon, R.S . Geha, andC. Terhorst . 1989 . Tcell antigen
receptor (TCR)-alpha/beta heterodimer formation is a prereq-
uisite for association of C133-zeta 2 into functionally compe- 22 .
tent TCR.CD3 complexes .J . Biol. Chem . 264:20760 .
8 . Geisler, C., J. Scholler,M.A. Wahi, B . Rubin, andA. Weiss .
1990 . Association of the human CD3-~chain with the a(iT
cell receptor/CD3 complex . J. Immunol. 141:1761 . 23 .
9 . Blumberg, R.S ., S. Ley, J . Sancho, N . Lonberg, E. Lacy, F .
McDermott, V . Scand,J.L . Greenstein, andC. Terhorst . 1990 .
Structure of theT cell antigen receptor: evidence fortwo CD3e
subunits in theT cell receptor/CD3 complex . Proc. Natl. Acad. 24 .
Sci. USA . 87:7220.
10 . Regueiro,J.R., A. ArnaizVillena,M . Ortiz deLandazuri, J.M.
MartinVilla, J.L . Vicario, V . Pascual-Ruiz, F . Guerra-Garcia,
J . Alcami,M . Lopez-Botet, andJ . Manzanares. 1986 . Familial 25 .
defect ofCD3 (T3) expression byT cells associated with rare
gut epithelial cell autoantibodies . Lancet. 1:1274 .
11 . Alarcon, B., J.R . Regueiro,A. ArnaizVillena, andC. Terhorst. 26 .
1988 . Familial defect in the surface expression of the Tcell
receptor-CD3 complex. N . Engl.J. Med . 319:1203 .
12 . Wileman, T, G.R . Carson,M. Concino, A. Ahmed, andC.
Terhorst . 1990. The y and e subunits of the CD3 complex 27 .
inhibit pre-Golgi degradation of newly synthesized Tcell an-
tigen receptors.J. Cell. Biol. 110:973 .
13 . Lerch, P.G., M. van de Rijn,J.E. Smart, R.W. Knowles, and
C. Terhorst . 1986 . Isolation and purification of the human
thymocyte antigens T6 and M241 . Mol. Immunol . 23:131 .
14 . Carrell, S., A. Moretta, G . Pantaleo, G. Tambussi, P . Isler, B . 28 .
Perussia, andJ.C . Cerottini. 1988 . Stimulation and prolifera-
tion ofCD4' peripheral blood T lymphocytes inducedby an
anti-CD4 monoclonal antibody. Eur .J . Immunol . 18:333 .
15 . Oettgen, H.C ., C.L . Pettey,WL. Maloy, and C. Terhorst .